Portal de Periódicos da CAPES

Guideline Application in Real world: multi-Institutional Based survey of Adjuvant and first-Line pancreatic Ductal adenocarcinoma treatment in Italy. Primary analysis of the GARIBALDI survey

2023; Elsevier BV; Volume: 8; Issue: 1 Linguagem: Inglês

10.1016/j.esmoop.2022.100777

2059-7029

Michele Reni, Elisa Giommoni, Francesca Bergamo, Michèle Milella, Luigi Cavanna, Maria Cristina Di Marco, M Spada, Stefano Cordio, Giuseppe Aprile, Giovanni Gerardo Cardellino, Evaristo Maiello, Ilaria Bernardini, Michele Ghidini, Silvia Bozzarelli, Marina Macchini, Giulia Orsi, Irene De Simone, Er. Rulli, Luca Porcu, Valter Torri, Carmine Pinto, Michele Reni, Marina Macchini, Giulia Orsi, Umberto Peretti, Mariamaddalena Valente, Elisa Giommoni, Lorenzo Antonuzzo, Francesco Di Costanzo, Francesca Bergamo, Vittorina Zagonel, Sara Lonardi, Federica Buggin, Michèle Milella, Silvia Palmerio, Luigi Cavanna, Camilla Di Nunzio, Maria Cristina Di Marco, Elisa Grassi, M Spada, Marco Messina, Stefano Cordio, Francesco Avola, Giuseppe Aprile, Salvatore Pagano, Francesca Simionato, Giovanni Gerardo Cardellino, Federica Majer, Evaristo Maiello, Tiziana Pia Latiano, Cinzia Chiarazzo, Fabrizio Artioli, Giorgia Razzini, Antonella Pasqualini, Michele Ghidini, Elisa Binda, Silvia Lazzarelli, Silvia Bozzarelli, Simona Sala, Gabriele Luppi, Elisa Pettorelli, Andrea Spallanzani, Giovanni Vicario, F. Salmaso, Marco Basso, Nicola Silvestris, Sabina Del Curatolo, Fable Zustovich, Francesca Bongiovanni, Ciro Longobardi, Ilenia Sandi, Caterina Fontanella, Silvia Montelatici, Monica Giordano, Giovanna Luchena, Micol Gilardoni, Emiliano Tamburini, Britt Rudnas, B. Venturini, Barbara Merelli, Giorgia Negrini, Elio Maria Vici, Alessandra Marabese, Cristina Garetto, Paola Curcio, Saverio Cinieri, M. Cinefra, Pasqualinda Ferrara, Maurizio Cantore, Patrizia Morselli, Guglielmo Fumi, Agnese Isidori, Giovanni Ciccarese, Giovanni Luca Frassineti, Flavia Pagan, Vanja Vaccaro, Chiara Spoto, Marianna Ferrara, Carlo Garufi, Marta Caporale, Enrico Vasile, Francesca Salani, Elisa Barone, Rossana Berardi, Azzurra Onofri, Zelmira Ballatore, Alessandra Lucarelli, Alessandra Barucca, Amedeo Pancotti, Teresa Scipioni, Katia Bencardino, Giovanna Marrapese, Laura Idotta, Fausto Petrelli, Veronica Lonati, Anna Ceribelli, A. Giuli, Cristina Zannori, Maria Bassanelli, Andrea Mambrini, Laura Ginocchi, Massimo Orlandi, Luigi Celio, Monica Niger, Lavinia Biamonte, Stefano Tamberi, Alessandra Piancastelli, Giorgio Papiani, Irene Valli, P. Allione, Maria Giovanna Boe, Mario Scartozzi, Eleonora Lai, Annagrazia Pireddu, Pina Ziranu, Laura Demurtas, Marco Puzzoni, Stefano Mariani, Andrea Pretta, Nicole Liscia, Clementina Savastano, Valentina Malaspina, Giuseppe Tonini, Teresa Grassani, Barbara Barco, Pierosandro Tagliaferri, Domenico Ciliberto, Antonella Ierardi, Natale Daniele Calandruccio, Vincenzo Minotti, Roberta Matocci, Valter Torri, Luca Porcu, Erica Rulli, Irene De Simone, Luciano Carlucci, Eliana Rulli, Davide Poli, Paola Tonto, Francesca Scellato, Carmine Pinto,

Colorectal Cancer Treatments and Studies

Background: Information about the adherence to scientific societies guidelines in the 'real-world' therapeutic management of oncological patients are lacking.This multicenter, prospective survey was aimed to improve the knowledge relative to 2017-2018 recommendations of the Italian Association of Medical Oncology (AIOM).Patients and methods: Treatment-naive adult patients with pancreatic adenocarcinoma were enrolled.Group A received adjuvant therapy, group B received primary chemotherapy, and group C had metastatic disease.The results on patients accrued until 31 October 2019 with a mature follow-up were presented.Results: Since July 2017, 833 eligible patients of 923 (90%) were enrolled in 44 Italian centers.The median age was 69 years (range 36-89 years; 24% >75 years); 48% were female; 93% had Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 or 1; group A: 16%, group B: 30%; group C: 54%; 72% Nord, 13% Center, 15% South.In group A, guidelines adherence was 68% [95% confidence interval (CI) 59% to 76%]; 53% of patients received gemcitabine and 15% gemcitabine þ capecitabine; median CA19.9 was 29 (range 0-7300; not reported 15%); median survival was 36.4 months (95% CI 27.5-47.3months).In group B, guidelines adherence was 96% (95% CI 92% to 98%); 55% of patients received nab-paclitaxel þ gemcitabine, 27% FOLFIRINOX, 12% gemcitabine, and 3% clinical trial; median CA19.9 was 337 (range 0-20220; not reported 9%); median survival was 18.1 months (95% CI 15.6-19.9months).In group C, guidelines adherence was 96% (95% CI 94% to 98%); 71% of patients received nabpaclitaxel þ gemcitabine, 16% gemcitabine, 8% FOLFIRINOX, and 4% clinical trial; liver and lung metastases were reported in 76% and 23% of patients, respectively; median CA19.9 value was 760 (range 0-1374500; not reported 9%); median survival was 10.0 months (95% CI 9.1-11.1 months).Conclusions: The GARIBALDI survey shows a very high rate of adherence to guidelines and survival outcome in line with the literature.CA19.9 testing should be enhanced; nutritional and psychological counseling represent an unmet need.Enrollment to assess adherence to updated AIOM guidelines is ongoing.